ArticleParasites & vectors2015
Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.
Article in Parasites & vectors, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 238 citations in OpenAlex.
- Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review.Parasites & vectors · 2016Pooled it
- Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection.PLoS neglected tropical diseases · 2022Trial
- Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Trial
- Comparison of Doxycycline, Minocycline, Doxycycline plus Albendazole and Albendazole Alone in Their Efficacy against Onchocerciasis in a Randomized, Open-Label, Pilot Trial.PLoS neglected tropical diseases · 2017Trial
- Modelling anti-Ov16 seroprevalence for the control and elimination of onchocerciasis.Nature communications · 2026Article
- Modelling the impact of mass drug administration with ivermectin or moxidectin on human onchocerciasis when there is sub-optimal response of parasites to treatment.Research square · 2026Article
- Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021-2023: results of screening for clinical trials of moxidectin versus ivermectin.Parasites & vectors · 2026Article
- Modelling transmission thresholds and hypoendemic stability for onchocerciasis elimination.PLoS computational biology · 2025Article
- Onchocerciasis is not a major cause of blindness in two endemic villages in Sierra Leone.BMC research notes · 2025Article
- Factors Associated With Coverage in Community-directed Treatment With Ivermectin for Onchocerciasis Control in Savanah and Forest Areas in Central African Republic: A Cross-sectional Study.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024Article
- Oxidative Stress and Chronic Myeloid Leukemia: A Balance between ROS-Mediated Pro- and Anti-Apoptotic Effects of Tyrosine Kinase Inhibitors.Antioxidants (Basel, Switzerland) · 2024Review
- Progress towards elimination of onchocerciasis in the Region du Sud-Ouest of Burkina Faso which was previously subject to a recrudescence event after vector control.PLoS neglected tropical diseases · 2024Article
- Community's knowledge, perceptions and preventive practices on Onchocerciasis in Jimma zone, Ethiopia, formative mixed study.PLoS neglected tropical diseases · 2024Article
- Impact of annual community-directed treatment with ivermectin on the incidence of epilepsy in Mvolo, a two-year prospective study.PLoS neglected tropical diseases · 2024Article
- Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Article
- AssessingPathogens (Basel, Switzerland) · 2023Article
- Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness.PLoS neglected tropical diseases · 2023Article
- Application of loop mediated isothermal amplification (LAMP) assays for the detection ofFrontiers in tropical diseases · 2023Article
- Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study.The Lancet. Global health · 2022Article
- The filarial and the antibiotics: Single or combination therapy using antibiotics for filariasis.Frontiers in cellular and infection microbiology · 2022Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe World Health Organization (WHO) has set ambitious targets for the elimination of onchocerciasis by 2020-2025 through mass ivermectin treatment. Two different mathematical models have assessed the feasibility of reaching this goal for different settings and treatment scenarios, namely the individual-based microsimulation model ONCHOSIM and the population-based deterministic model EPIONCHO. In this study, we harmonize some crucial assumptions and compare model predictions on common outputs.
methodsUsing a range of initial endemicity levels and treatment scenarios, we compared the models with respect to the following outcomes: 1) model-predicted trends in microfilarial (mf) prevalence and mean mf intensity during 25 years of (annual or biannual) mass ivermectin treatment; 2) treatment duration needed to bring mf prevalence below a provisional operational threshold for treatment interruption (pOTTIS, i.e. 1.4 %), and 3) treatment duration needed to drive the parasite population to local elimination, even in the absence of further interventions. Local elimination was judged by stochastic fade-out in ONCHOSIM and by reaching transmission breakpoints in EPIONCHO.
resultsONCHOSIM and EPIONCHO both predicted that in mesoendemic areas the pOTTIS can be reached with annual treatment, but that this strategy may be insufficient in very highly hyperendemic areas or would require prolonged continuation of treatment. For the lower endemicity levels explored, ONCHOSIM predicted that the time needed to reach the pOTTIS is longer than that needed to drive the parasite population to elimination, whereas for the higher endemicity levels the opposite was true. In EPIONCHO, the pOTTIS was reached consistently sooner than the breakpoint.
conclusionsThe operational thresholds proposed by APOC may have to be adjusted to adequately reflect differences in pre-control endemicities. Further comparative modelling work will be conducted to better understand the main causes of differences in model-predicted trends. This is a pre-requisite for guiding elimination programmes in Africa and refining operational criteria for stopping mass treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.